true
0001053369
0001053369
2025-11-10
2025-11-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K/A
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D)
OF
THE SECURITIES EXCHANGE ACT OF 1934
November 10, 2025
Date
of Report (Date of earliest event reported)
ELITE
PHARMACEUTICALS INC /NV/
ELITE
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
| Nevada |
|
001-15697 |
|
22-3542636 |
| (State
or other jurisdiction |
|
(Commission |
|
(IRS
Employer |
| of
incorporation) |
|
File
Number) |
|
Identification
No.) |
165
Ludlow Avenue, Northvale,
New Jersey 07647
(Address
of principal executive offices)
(201)
750-2646
(Registrant’s
telephone number, including area code)
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, par value $0.001 per share |
|
ELTP |
|
OTCQB |
Explanatory
Note
This
Current Report on Form 8-K/A amends the Current Report on Form 8-K filed by Elite Pharmaceuticals, Inc. (the “Company”) on
November 10, 2025, solely to correct the date of the conference call in Item 7.01.
Item
7.01. Regulation FD Disclosure.
On
November 10, 2025, Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) issued a press release announcing that
the company will host a conference call to discuss its financial results for the second quarter of fiscal year 2026 ended September 30,
2025, on Monday, November 17, 2025, at 11:30 AM EST. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated
by reference herein.
Conference
Call Information
| Date:
|
|
November
17, 2025 |
| Time:
|
|
11:30
AM EST |
| Dial-in
numbers: |
|
1-800-346-7359
(domestic) |
| |
|
1-973-528-0008
(international) |
| Conference
number: |
|
98840 |
| Questions: |
|
dianne@elitepharma.com
|
| |
|
General
questions by 5:00 PM EST on Thursday, November 13, 2025 |
| |
|
Financial
questions by 7:00 PM EST on Friday, November 14, 2025 |
The
information disclosed in Item 2.02 above is incorporated into this Item 7.01. The information included in this Current Report on Form
8-K (including the exhibit hereto) is being furnished under Item 2.02, “Results of Operations and Financial Condition,” Item
7.01, “Regulation FD Disclosure” and Item 9.01 “Financial Statements and Exhibits” of Form 8-K. As such, the
information (including the exhibit) herein shall not be deemed to be “filed” for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall
it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general
incorporation language in such filing, except as shall be expressly set forth by specific reference in such a filing. This Current Report
(including the exhibit hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely
to satisfy the requirements of Regulation FD.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
| Exhibit
No. |
|
Description |
| 99.1 |
|
Press Release dated November 10, 2025 |
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| Dated:
November 12, 2025 |
ELITE
PHARMACEUTICALS, INC. |
| |
By: |
/s/
Nasrat Hakim |
| |
|
Nasrat
Hakim, President and CEO |
